Lyrica® generic delayed until summer 2019 and Pfizer to increase drug prices

This is a cross-post from our Optum Insights blog. The U.S. Food and Drug Administration’s (FDA) recent decision to grant pediatric exclusivity for Lyrica® ― as it may be used as an adjunctive therapy for partial onset seizures in pediatric epilepsy patients ― extends the period of market exclusivity in the U.S. by an additional … Read moreLyrica® generic delayed until summer 2019 and Pfizer to increase drug prices

Drug Update: Generic Nexium, Esomeprazole Released

Another highly utilized medication within the workers’ compensation industry has had its patent expire and the generic equivalent approved for release onto the market. On January 26, 2015, the U.S. Food and Drug Administration (FDA) approved the generic version of brand Nexium, Esomeprazole. Nexium (Esomeprazole) is a proton pump inhibitor most often utilized in the … Read moreDrug Update: Generic Nexium, Esomeprazole Released

CMS Comments on Hydrocodone Combination Product Coverage Changes in Relation to WCMSAs

As of October 6th, 2014, the rescheduling of all hydrocodone combination products to the Schedule II classification went into effect. As previously discussed in our September 15, 2014, “DEA Classification Change for Hydrocodone Combination Products (HCPs)” blog, there were restrictions and changes related to the reclassification that could possibly lead to increase costs and ultimately … Read moreCMS Comments on Hydrocodone Combination Product Coverage Changes in Relation to WCMSAs

DEA Classification Change for Hydrocodone Combination Products (HCPs)

When the Controlled Substances Act was passed in 1970, pure hydrocodone was classified as Schedule II, while its combination products, HCPs, (those containing hydrocodone as well as specific amounts of other medications such as acetaminophen or ibuprofen) were classified as Schedule III.  On Friday, August 22, 2014, the DEA published a final rule in the Federal … Read moreDEA Classification Change for Hydrocodone Combination Products (HCPs)